SCHEMBL26653822

SCHEMBL26653822

Cn1c(C2CNC2)cc2nnc(-c3ccccc3O)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.42
▸ PBRM1 Q86U86 12/20 0.39
▸ SMARCA2 P51531 11/20 0.39
▸ SMARCA4 P51532 11/20 0.39
▸ HSD17B10 Q99714 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NR1I2 O75469 7/20 0.37
▸ IKBKB O14920 2/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ CHUK O15111 1/20 0.37
▸ NR1H2 P55055 2/20 0.37
▸ NR1H3 Q13133 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26653819 0.88 PBRM1 (0.43) PDE10APBRM1SMARCA2SMARCA4HSD17B10
SCHEMBL26654139 0.82 PBRM1 (0.37) PBRM1SMARCA2SMARCA4HSD17B10NR1I2
SCHEMBL26654073 0.81 PBRM1 (0.36) PBRM1SMARCA2SMARCA4NR1I2IKBKB
SCHEMBL26654087 0.77 SMARCA2 (0.52) PDE10APBRM1SMARCA2SMARCA4KDM4E
SCHEMBL26653968 0.76 IKBKB (0.39) PBRM1SMARCA2SMARCA4NR1I2IKBKB
SCHEMBL26654141 0.76 IKBKB (0.39) PBRM1SMARCA2SMARCA4NR1I2IKBKB
SCHEMBL26654149 0.76 IKBKB (0.39) PBRM1SMARCA2SMARCA4NR1I2IKBKB
SCHEMBL30658025 0.75 SMARCA2 (0.55) PBRM1SMARCA2SMARCA4MAPTKDM4E
SCHEMBL26653859 0.75 PBRM1 (0.55) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL30658005 0.74 PBRM1 (0.38) PDE10APBRM1SMARCA2SMARCA4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
CN-120035593-A Pyrazine derivatives and uses thereof 福宏治疗公司 2025-05-23 — — CN disclosed
EP-4522279-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
WO-2023220134-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed
WO-2023220134-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF BRCA1, VHL, SF3B5 PDE10A 2159/4885PBRM1 7/4885SMARCA2 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback